Rare Disease and Orphan Drugs Journal Accepted for Inclusion in Scopus

We are delighted to announce that on May 7, 2025, Rare Disease and Orphan Drugs Journal (RDODJ) was officially accepted for inclusion in Scopus, one of the world’s largest and most respected abstract and citation databases for peer-reviewed literature.

This significant milestone reflects the journal’s unwavering commitment to high academic standards, rigorous peer review, and its vital role in advancing research in the field of rare diseases and orphan drugs. Inclusion in Scopus will enhance the visibility, accessibility, and citation potential of the journal’s publications, offering our authors and readers expanded opportunities for global impact.

Since its launch, RDODJ has aimed to provide a dedicated platform for the dissemination of high-quality research, clinical insights, policy analysis, and patient-centered perspectives in this critically important yet often underserved area. Indexing in Scopus further affirms the relevance and scientific merit of the journal’s content.

We extend our sincere gratitude to our Editorial Board members, reviewers, authors, and readers for their continued support and contributions, which have made this achievement possible. We look forward to furthering our mission to promote excellence in research and improve outcomes for individuals living with rare conditions.

Managing Editor: Yuan Ding
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully submitted by the Editorial Office of Rare Disease and Orphan Drugs Journal